Argimesna

Drug Profile

Argimesna

Latest Information Update: 13 Mar 1997

Price : $50

At a glance

  • Originator Bayer Schering Pharma
  • Developer Bayer Schering Pharma; Farmades
  • Class Antineoplastics; Basic amino acids; Diamino amino acids; Essential amino acids; Uroprotectives
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Bladder cancer; Cystitis; Nephritis

Most Recent Events

  • 13 Mar 1997 Discontinued-II for Bladder cancer in Germany (Unknown route)
  • 13 Mar 1997 Discontinued-II for Bladder cancer in Italy (Unknown route)
  • 13 Mar 1997 Discontinued-II for Cystitis in Germany (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top